


E(c(RGDfK))2

Cat. No.: HY-P5098
CAS No.: 250612-47-6
Molecular Formula: C₅₉H₈₇N₁₉O₁₆
Molecular Weight: 1318
Sequence: Glu[cyclo(Arg-Gly-Asp-{d-Phe}-Lys)]-cyclo(Arg-Gly-Asp-{d-Phe}-Lys)
Sequence Shortening: E[cyclo(RGD-{d-Phe}-K)]-cyclo(RGD-{d-Phe}-K)
Target: Others
Pathway: Others
Storage: Sealed storage, away from moisture



Powder -80°C 2 years
 -20°C 1 year
 * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (75.87 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	0.7587 mL	3.7936 mL	7.5873 mL
	5 mM	0.1517 mL	0.7587 mL	1.5175 mL
	10 mM	0.0759 mL	0.3794 mL	0.7587 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

E(c(RGDfK)) is an αβ3 integrin-specific binding moiety with tumor targeting properties. Increased uptake of E(c(RGDfK)) in human ovarian cancer OVCAR-3 xenograft tumors may be useful in cancer research^[1].

REFERENCES

[1]. Polyak D, et al. Development of PEGylated doxorubicin-E-[c (RGDfK) 2] conjugate for integrin-targeted cancer therapy[J]. Polymers for Advanced Technologies, 2011, 22(1): 103-113.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA